<DOC>
	<DOC>NCT02595450</DOC>
	<brief_summary>This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.</brief_summary>
	<brief_title>A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>It is the physician's decision to prescribe erlotinib in participants and to document their treatment Participants must be candidates for receiving erlotinib for locally advanced or metastatic nonsmall cell lung cancer according to the product label Participants will be excluded if safety concerns occurred If the participant was not compliant or if the participant would wish to stop erlotinib therapy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>